These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37190307)

  • 1. Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma.
    Nishida N; Aoki T; Morita M; Chishina H; Takita M; Ida H; Hagiwara S; Minami Y; Ueshima K; Kudo M
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents.
    Nishida N; Kudo M
    Liver Cancer; 2024 Apr; 13(2):136-149. PubMed ID: 38751556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.
    Qiu Z; Ji J; Xu Y; Zhu Y; Gao C; Wang G; Li C; Zhang Y; Zhao J; Wang C; Wen X; Zhang Z; Li B; Zhang Z; Cai S; Li B; Jiang X
    BMC Med; 2022 Feb; 20(1):64. PubMed ID: 35130881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
    Jusakul A; Cutcutache I; Yong CH; Lim JQ; Huang MN; Padmanabhan N; Nellore V; Kongpetch S; Ng AWT; Ng LM; Choo SP; Myint SS; Thanan R; Nagarajan S; Lim WK; Ng CCY; Boot A; Liu M; Ong CK; Rajasegaran V; Lie S; Lim AST; Lim TH; Tan J; Loh JL; McPherson JR; Khuntikeo N; Bhudhisawasdi V; Yongvanit P; Wongkham S; Totoki Y; Nakamura H; Arai Y; Yamasaki S; Chow PK; Chung AYF; Ooi LLPJ; Lim KH; Dima S; Duda DG; Popescu I; Broet P; Hsieh SY; Yu MC; Scarpa A; Lai J; Luo DX; Carvalho AL; Vettore AL; Rhee H; Park YN; Alexandrov LB; Gordân R; Rozen SG; Shibata T; Pairojkul C; Teh BT; Tan P
    Cancer Discov; 2017 Oct; 7(10):1116-1135. PubMed ID: 28667006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
    Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
    J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
    Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A High Epigenetic Risk Score Shapes the Non-Inflamed Tumor Microenvironment in Breast Cancer.
    Zhang D; Wang Y; Yang Q
    Front Mol Biosci; 2021; 8():675198. PubMed ID: 34381812
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges.
    Indini A; Massi D; Pirro M; Roila F; Grossi F; Sahebkar A; Glodde N; Bald T; Mandalà M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):477-490. PubMed ID: 35752398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteogenomic characterization of cholangiocarcinoma.
    Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
    Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma.
    Nanok C; Jearanaikoon P; Proungvitaya S; Limpaiboon T
    Mol Med Rep; 2018 Mar; 17(3):4145-4153. PubMed ID: 29359783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer.
    Ye F; Liang Y; Hu J; Hu Y; Liu Y; Cheng Z; Ou Y; Xu C; Jiang H
    Front Cell Dev Biol; 2021; 9():760369. PubMed ID: 34926451
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. m
    Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
    Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
    Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
    Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma.
    Andresen K; Boberg KM; Vedeld HM; Honne H; Jebsen P; Hektoen M; Wadsworth CA; Clausen OP; Lundin KE; Paulsen V; Foss A; Mathisen Ø; Aabakken L; Schrumpf E; Lothe RA; Lind GE
    Hepatology; 2015 May; 61(5):1651-9. PubMed ID: 25644509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
    Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
    J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
    Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
    J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
    Nguyen CT; Caruso S; Maille P; Beaufrère A; Augustin J; Favre L; Pujals A; Boulagnon-Rombi C; Rhaiem R; Amaddeo G; di Tommaso L; Luciani A; Regnault H; Brustia R; Scatton O; Charlotte F; Brochériou I; Sommacale D; Soussan P; Leroy V; Laurent A; Le VK; Ta VT; Trinh HS; Tran TL; Gentien D; Rapinat A; Nault JC; Allaire M; Mulé S; Zucman-Rossi J; Pawlotsky JM; Tournigand C; Lafdil F; Paradis V; Calderaro J
    Clin Cancer Res; 2022 Feb; 28(3):540-551. PubMed ID: 34785581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
    Goeppert B; Roessler S; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil A; Czink E; Köhler B; Springfeld C; Pfeiffenberger J; Rupp C; Weiss KH; Schirmacher P; von Knebel Doeberitz M; Kloor M
    Br J Cancer; 2019 Jan; 120(1):109-114. PubMed ID: 30377340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.